When the Food and Drug Administration gave the OK to a new treatment for a parasitic disease called leishmaniasis in late March, the Canadian company that owns the medicine got something that's quite likely to prove even more valuable than U.S. sales of the drug will ever be.
Would anyone still "like to buy the world a Coke"?
Yes, it's tough times for Big Soda in the U.S. The numbers alone make it clear. "The entire [U.S.] carbonated soft drink category has been down for nine years," says John Sicher, editor of Beverage Digest. "Diet [soft drinks] are declining at a steeper pace than sugared [soft drinks]," likely because people are concerned about artificial ingredients.
The federal Medicare program for the elderly and disabled will cover two new drugs that can cure hepatitis C, a liver disease that can cause cancer and lead to death. The drugs are very expensive, but they cure hepatitis C in most cases. The government and insurers are concerned about these costs; three million Americans have hepatitis C, most of whom don't know they have it.